Business
Plus Therapeutics Announces Read Out of Type B Meeting with the FDA with Goal of Accelerating Approval of REYOBIQ™ for Leptomeningeal Metastases
On track to define optimal dosing interval and advance manufacturing scale up of REYOBIQ for pivotal trial readiness in late 2026HOUSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, announces the completion of a Type B meeting with the U.S. Food and Drug Administration (FDA) on next steps on REYOBIQ pi
About this update from Plus Therapeutics, Inc.
[{"type":"image","alt":"Plus Therapeutics Inc.","displaySize":"","headline":null,"caption":"Plus Therapeutics Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":172,"url":"https://media.zenfs.com/en/globenewswire.com/1d6738db871d52da7de4b5de8e51921c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/iUBJ3sPkI4ud4lMmyJb.Bg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTI0MTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/1d6738db871d52da7de4b5de8e51921c","width":300,"height":172}},"lazy":false},{"type":"text","content":"On track to define optimal dosing interval and advance manufacturing scale up of REYOBIQ for pivotal trial readiness in late 2026","length":129,"tagName":"p"},{"type":"text","content":"HOUSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, announces the completion of a Type B meeting with the U.S. Food and Drug Administration (FDA) on next steps on REYOBIQ pivotal trial strategy for leptomeningeal metastases (LM). The meeting resulted in constructive discussion with the FDA regarding key elements of the potential pivotal study design for REYOBIQ in LM. Plus intends to incorporate the FDA’s feedback in the current dose optimization trial and seek alignment with the FDA on a revised protocol, likely later this year. The company’s goal is to be ready for a potential pivotal trial following completion of the current dose optimization trial and, ultimately, work towards the potential approval of REYOBIQ for patients affected by LM.","length":960,"tagName":"p"},{"type":"text","content":"Highlights of FDA responses to the Company's key enquiries:","length":63,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Accelerated approval – FDA indicated that accelerated approval may be appropriate for the LM indication, but there are insufficient data to support the use of circulating tumor cells (CTCs) as an intermediate clinical endpoint. FDA and Plus discussed that additional steps would be necessary to validate CTCs as a surrogate endpoint to potentially support other future applications.","length":382,"tagName":"p"}]},{"val":[{"type":"text","content":"Primary and key endpoints – FDA rec...